ELIQUENT
LIFE SCIENCES

Case Study

Sell-Side Assessment of Vaccine Manufacturer
Preparing for Third-Party Diligence Following Key Data Release

Objective

Support an early-stage biotech company by providing a clinical and regulatory review in anticipation of third-party diligence following proof-of-concept data release.



Challenge

Engaged by an early-stage biotech focused on vaccine development that sought a strategic clinical and regulatory review of its development history, early clinical and non-clinical data, and proposed development program in anticipation of third-party diligence following proof-of-concept data release.



Solution

Assembled a team of former senior FDA leadership to provide an assessment of the interactions to date with global health authorities, likely data expectations for regulatory approval, potential risks/opportunities with the vaccine program as executed to date, and the company's proposed clinical trial design and regulatory pathway. Identified key issue areas that would likely arise during third-party diligence and worked with the company on response strategies and recommendations for how to design/implement a pivotal program for regulatory approval. Also provided strategic input on the framework and content of the virtual data room assembled for purposes of third-party diligence.

Outcome

Client utilized the engagement to both prepare for upcoming diligence activity and share the expert assessment with interested parties. Resulted in an oversubscribed funding round with multiple high-profile private equity firms participating.

Due Diligence Solutions

ELIQUENT's expanded due diligence platform leverages the unmatched experience and robust institutional knowledge of the firm's regulatory experts to empower decisions and drive value. Learn more at **ELIQUENT.com**